Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024

The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023–Jan 2024), where a universal immunisation programme began late September (coverage...

Descripción completa

Detalles Bibliográficos
Autores: López Lacort, Mónica, Múñoz Quiles, Cintia, Mira Iglesias, Ainara, López Labrador, F. Xavier, Mengual Chuliá, Beatriz, Fernández García, Carlos, Carballido Fernández, Mario, Pineda Caplliure, Ana, Mollar Maseres, Juan, Benavent, Maruan Shalabi, Sanz Herrero, Francisco, Zornoza Moreno, Matilde, Pérez Martín, Jaime Jesús, Alfayate Miguelez, Santiago, Pérez Crespo, Rocío, Bastida Sánchez, Encarnación, Menasalvas Ruiz, Ana Isabel, Téllez González, Mª Cinta, Esquiva Soto, Samuel, Del Toro Saravia, Carlos, Sanz Muñoz, Iván, Eiros, José María, Matías Del Pozo, Vanesa, Toquero Asensi, Marina, Pastor Villalba, Eliseo, Lluch Rodrigo, José Antonio, Díez Domingo, Javier, Orrico Sánchez, Alejandro
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad Católica de Valencia San Vicente Mártir
Repositorio:RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
Idioma:inglés
OAI Identifier:oai:riucv.ucv.es:20.500.12466/4335
Acceso en línea:http://hdl.handle.net/20.500.12466/4335
Access Level:acceso abierto
Palabra clave:Nirsevimab immunoprophylaxis
Hospital admission
Respiratory syncytial virus lower
Respiratory tract infections
Infants
32 Ciencias Médicas
Descripción
Sumario:The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023–Jan 2024), where a universal immunisation programme began late September (coverage range: 79–99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making.

Similares en LA Referencia